Skip to main content

Gene Therapy at Nervous System

Medicine still has many challenges to solve specially on complex diseases were a large number of both, genetic and environmental factors are involved. Among them, neurodegenerative and autoimmune disorders affecting the central nervous system have attracted attention because CNS is difficult to access and to manipulate with classical pharmacological treatments and, in addition, there are no effective curative treatments for these diseases. To address these problems, we have focused our research interests in gene therapy strategies for autoimmune diseases and neurodegenerative disorders specially those associated to aging.
 

Team

Miguel Chillon Rodriguez

Miguel Chillon Rodriguez

Head of group
Gene Therapy at Nervous System
Read more
Anna Jeanne Behr

Anna Jeanne Behr

Predoctoral researcher
Gene Therapy at Nervous System
Read more
Chiara Piccinini

Chiara Piccinini

Predoctoral researcher
Gene Therapy at Nervous System
Read more
David Ramirez Gomez

David Ramirez Gomez

Predoctoral researcher
Gene Therapy at Nervous System
Read more
Edo Salvador, Angel

Edo Salvador, Angel

Postdoctoral researcher
Gene Therapy at Nervous System
Read more
Jiménez Hernández, Nerea

Jiménez Hernández, Nerea

Research technician
Gene Therapy at Nervous System
Read more
Miguel Chillon Rodriguez

Miguel Chillon Rodriguez

Head of group
Gene Therapy at Nervous System
Read more
Anna Jeanne Behr

Anna Jeanne Behr

Predoctoral researcher
Gene Therapy at Nervous System
Read more
Chiara Piccinini

Chiara Piccinini

Predoctoral researcher
Gene Therapy at Nervous System
Read more
David Ramirez Gomez

David Ramirez Gomez

Predoctoral researcher
Gene Therapy at Nervous System
Read more
Edo Salvador, Angel

Edo Salvador, Angel

Postdoctoral researcher
Gene Therapy at Nervous System
Read more
Jiménez Hernández, Nerea

Jiménez Hernández, Nerea

Research technician
Gene Therapy at Nervous System
Read more

Research lines

Gene Therapy Strategies for Esclerosis Multiple, an autoimmune disease affecting the nervous system

IP: -

Generation and development of more selective and less immunogenic viral vectors

IP: -

Molecular mechanisms involved in memory formation: Study of altered signaling pathways in CNS in non-pathogenic aging and in Alzheimer's Disease

IP: -

Projects

Bringing Klotho protein as a new therapy against age-associated muscle degeneration

IP: Joan Roig Soriano
Collaborators: Miguel Chillon Rodriguez, Elsa Ibarrola Carrasco, David Ramirez Gomez
Funding agency: Fundació Institut de Recerca HUVH
Funding: 10000
Reference: VHIR-FIT-24-002
Duration: 13/12/2024 - 12/12/2025

Towards an effective and safe therapy for hormonal-deficiency osteoporosis based on klotho protein

IP: Joan Roig Soriano
Collaborators: Miguel Chillon Rodriguez
Funding agency: Fundació "La Caixa"
Funding: 64450
Reference: CI24-20581
Duration: 15/10/2024 - 14/10/2026

ERDERA: European Rare Disease Research Alliance

IP: M Mar Mañu Pereira
Collaborators: Augusto Cesar Sao Aviles, Patricia González Ruiz, Claire Diot, Miguel Chillon Rodriguez, Simon Schwartz Navarro, Sara Isabel Reidel
Funding agency: EUROPEAN COMMISSION
Funding: 1252083.33
Reference: ERDERA/EC/HLTH-2023-DISEASE-07-01/2023/MAÑU
Duration: 01/09/2024 - 31/08/2031

Use of chimeric chronokines for neurodegenerative diseases and cognitive impairments associated with aging

IP: Miguel Chillon Rodriguez
Collaborators: Laia Perez Lasarte, David Ramirez Gomez
Funding agency: Fundació Institut de Recerca HUVH
Funding: 102820.06
Reference: VHIR-PHD-2023-007
Duration: 01/02/2024 - 30/01/2028

Thesis

Novel chronokine-based approaches to tackle multiple pathways in Alzheimer’s disease: secreted Klotho and newly designed chimeric HEBE.

PhD student: Jon Esandi Jauregui
Director/s: Miguel Chillon Rodriguez
University: Universitat Autònoma de Barcelona
Year: 2024

AAV-mediated expression of Secreted Klotho as a therapeutic strategy for Alzheimer’s disease

PhD student: Rebeca Blanch Garcia
Director/s: Miguel Chillon Rodriguez
University: Universitat Autònoma de Barcelona
Year: 2023

Safety and therapeutical efficacy of the antiageing protein klotho for treating age-associated deficits and increasing longevity

PhD student: Joan Roig Soriano, Joan Roig Soriano
Director/s: Miguel Chillon Rodriguez
University: Universitat Autònoma de Barcelona
Year: 2023

Desarrollo de nuevas estrategias de terapia génica como tratamiento inmunomodulador de la esclerosis múltiple

PhD student: Angel Edo Salvador
Director/s: Miguel Chillon Rodriguez, Xavier Montalban Gairín, Xavier Montalban Gairín
University:
Year: 2020

Generación de un adenovirus quimérico Ad5/52s pseudotipado con la proteína fiber corta del Ad52 para su caracterización in vitro e in vivo como vector de terapia génica

PhD student: Marc García Moure
Director/s: Miguel Chillon Rodriguez
University: Universidad Autònoma de Barcelona
Year: 2016

Blog

News

The donation will enable further characterisation of patients with this rare disease, the identification of new biomarkers and the exploration of innovative therapies.

The Gen Rebelde Foundation has made the first donation of the year to the gene therapy research project for GNB1 encephalopathy.

The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB) with the participation of VHIR.

Rates

Check the current rates for the services offered by the Gene Therapy at Nervous System research group.

Icona fitxers

Group Current Rates

PDF 0.48 MB

Icona fitxers

Group Rates (2021)

PDF 3.06 MB